Published in final edited form as:

J Int Neuropsychol Soc. 2020 February ; 26(2): 241–249. doi:10.1017/S1355617719001085.

Sex Differences in Cognitive Changes in De Novo Parkinson's Disease

Ece Bayram¹, Sarah J. Banks¹, Guogen Shan², Nikki Kaplan³, Jessica Z. K. Caldwell³

¹University of California San Diego, Department of Neurosciences, La Jolla, CA, USA.

²University of Nevada Las Vegas, Department of Environmental and Occupational Health, Las Vegas, NV, USA.

³Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA.

Abstract

Objective: To evaluate the sex differences in cognitive course over 4 years in Parkinson's disease (PD) patients with and without mild cognitive impairment (MCI) compared to controls.

Methods: Four-year longitudinal cognitive scores of 257 cognitively intact PD, 167 PD-MCI, and 140 controls from the Parkinson's Progression Markers Initiative were included. Longitudinal scores of men and women, and PD with and without MCI were compared.

Results: Women had better verbal memory, men had better visuospatial function. There was no interaction between sex, diagnostic group, and/or time (4-year follow-up period).

Conclusions: Sex differences in cognitive course in de novo PD are similar to healthy aging. Cognitive decline rates in PD with and without MCI are similar for the first 4 years of PD.

Keywords

Parkinson's disease; cognition; sex; longitudinal studies; memory; decline

Introduction

Cognitive impairment is a common non-motor symptom of Parkinson's disease (PD). At early stages, up to a third of PD patients fulfill diagnostic criteria for mild cognitive impairment (MCI) (Aarsland et al., 2010; Broeders et al., 2013; Litvan et al., 2011). Within 5 to 6 years, half of cognitively intact PD patients develop MCI, and all patients with MCI progress to dementia (Broeders et al., 2013; Pigott et al., 2015). Despite these stark statistics, some longitudinal studies with de novo PD show progression rates comparable to healthy controls (HC) (de la Riva, Smith, Xie, & Weintraub, 2014). This discrepancy may be due to inclusion of PD patients with varying levels of known risk factors for cognitive impairment, including increased age, longer disease duration, male sex, more severe motor symptoms,

non-motor symptoms such as neuropsychiatric disturbances, genetic factors, and comorbid Alzheimer's disease (AD) pathology (Aarsland et al., 2010; G. Liu et al., 2017).

In healthy individuals, sex is associated with different cognitive profiles across the lifespan; women generally perform better on verbal learning and memory, and men perform better on visuospatial tasks (Brunet, Caldwell, & Miller, 2018; Munro et al., 2012). Similar differences have been observed in PD (Liu et al., 2015). In addition, in PD patients with over 8 years of disease, men show higher risk for dementia and faster decline once cognitively impaired (Cholerton et al., 2018). This is in contrast to AD, where women have more rapid declines once impaired (Burke et al., 2018). Better understanding of sex-based differences in risk for and trajectory of cognitive decline in newly diagnosed PD patients may help shape treatment approaches or clinical management of early cognitive impairments.

In this study, we investigated changes in cognitive scores over time in men and women newly diagnosed with PD using the Parkinson's Progression Markers Initiative (PPMI) database. We evaluated whether men would deteriorate faster than women, as male sex has been reported as a risk factor for dementia in PD patients with longer disease duration (Cholerton et al., 2018). Depression and anxiety impact cognition and brain functioning (Dotson et al., 2014), and excessive daytime sleepiness is a risk factor for cognitive decline in healthy populations (Jaussent et al., 2012). We assessed whether deterioration rate was faster and whether the cognitive scores declined more in the PD-MCI compared to cognitively intact PD independent of mood, sleepiness and motor impairment changes. Finally, as the apolipoprotein E gene $\epsilon 4$ allele (APOE- $\epsilon 4$) is a common AD risk factor and is associated with executive dysfunction in PD (Samat, Abdul Murad, Mohamad, Abdul Razak, & Mohamed Ibrahim, 2017); differences in APOE- $\epsilon 4$ frequency across groups were investigated.

Method

Data were downloaded from the PPMI website on May 10, 2018 (<http://www.ppmi-info.org/>). The PPMI is a multi-site study collecting data on aspects of PD longitudinally. Design and aims have been previously published (Marek et al., 2011) and can be found on their website (<http://www.ppmi-info.org/study-design>). The PPMI was approved by the institutional review boards of all participating sites, and all participants provided written informed consent.

In our study, patients were separated into two groups: PD-normal cognition (PD-NC) ($n = 257$) and PD-MCI ($n = 167$). MCI was defined by standard scores of -1.5 SD below appropriate norms on at least two cognitive tests (Litvan et al., 2012). The HC ($n = 140$) consisted of individuals 30 years or older with no current or active clinically significant neurological disorder, and no first-degree relative with idiopathic PD; cognitively intact with a Montreal Cognitive Assessment (MoCA) score >26 , and standard scores within 1.5 SD of appropriate norms on the cognitive battery.

Cognitive battery

All available cognitive tests were included. MoCA – a screening measure assessing attention, working memory, executive function, visuospatial function, language, orientation with the total score ranging from 0 to 30 – was used to index global cognition (Nasreddine et al., 2005). Phonemic fluency was assessed by the MoCA (total number of words beginning with a specific letter produced within 1 min). Hopkins Verbal Learning Test-Revised (HVLTR) is a verbal learning/memory test consisting of a list of 12 words presented in three repeated learning trials, followed by a minimum 20-min delayed recall and recognition (Benedict, Schretlen, Groninger, & Brandt, 1998). Benton Judgment of Line Orientation 15-item (JLO) is a 15-item spatial perception and orientation measure requiring matching two angled lines to a set of 11 lines arranged in a semicircle (Benton, Varney, & Hamsher, 1978). Symbol-Digit Modalities Test (SDMT) is a processing speed test requiring transposition of symbols for 90 s, following a key (Smith, 1968). Wechsler Memory Scale-III Letter Number Sequencing (LNS) is a verbal working memory measure, including auditory presentation of letter and number sequences, requiring recitation of first the numbers in an ascending order and then the letters in an alphabetical order (Wechsler, 1997). Animal naming is a semantic fluency test requiring naming as many animals as possible in 1 min (Rosen, 1980). Higher scores indicate better performance for all.

Other assessments

The 15-item Geriatric Depression Scale (GDS) is a self-report scale measuring depressive symptoms (Meara, Mitchelmore, & Hobson, 1999). State and Trait Anxiety Inventory (STAI) consists of self-report of state and trait anxiety (Spielberger, Gorsuch, & Lushene, 1970). Epworth Sleepiness Scale (ESS) is a self-report scale of sleepiness in daily activities (Johns, 1991). Motor impairment in PD was assessed using Movement Disorders Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III (Goetz et al., 2008). Higher scores indicate worse symptoms for all.

Statistical analysis

Data were analyzed using IBM SPSS version 23 (Armonk, NY) and SAS (SAS Institute Inc., Cary, NC). Cognitive and other assessment scores from baseline and annual follow-up visits (years 1, 2, 3, 4) were analyzed. Demographics and baseline scores were compared between groups using Chi-square tests, independent samples t tests and analysis of variance (ANOVA). Longitudinal changes in other assessments were evaluated using repeated measures ANOVA. Longitudinal course of cognition was evaluated with repeated measures analysis of covariance. Years of education and MDS-UPDRS Part III were not matched, thus included as covariates. Longitudinal GDS, STAI, ESS were included as covariates due to previously reported cognitive associations and significant differences between diagnostic groups and/or sexes in our sample. Sidak correction was used for multiple comparisons. $p < .05$ was considered statistically significant.

Results

Demographics, clinical features and other assessment scores

Baseline comparisons: Descriptive statistics and comparisons for demographics, clinical features, other assessment scores at baseline are given in Table 1. There were no significant diagnostic groups by sex interaction effects on any of these measures. Women had less years of education, higher STAI-Trait than men, and showed a trend toward younger age. APOE- ϵ 4 frequency, GDS, ESS, STAI-State, disease duration, HYS, MDS-UPDRS Part III were similar between men and women. Regarding diagnosis, PD-MCI was less educated than HC and PD-NC, though education was similar for HC and PD-NC. HC had lower STAI than both PD groups, with no STAI difference between PD groups. PD-MCI had higher MDS-UPDRS Part III than PD-NC. Age, APOE- ϵ 4 frequency, GDS, ESS were similar across diagnostic groups. Disease duration and HYS did not differ between PD groups.

Longitudinal comparisons: Results are presented in Supplementary Table 1. GDS, STAI, MDS-UPDRS Part III did not change over time, while ESS increased over time. Men had higher ESS, lower STAI-Trait compared to women, though GDS and STAI-State were similar across sexes. Both PD groups had higher STAI and ESS than HC. PD-MCI showed a trend toward higher GDS compared to HC, but GDS was not different between PD-NC and HC. The only significant difference between PD-NC and PD-MCI was MDS-UPDRS Part III, with higher scores for the PD-MCI. The only diagnostic group and sex interaction effect was for MDS-UPDRS Part III, with difference between the PD-NC and PD-MCI more pronounced in women.

Cognition

Baseline comparisons: Descriptive statistics and comparisons at baseline are shown in Table 1. Women scored higher on HVLT-R learning and delayed recall; lower on JLO. MoCA, phonemic fluency, SDMT, LNS, animal naming were similar between men and women. Regarding diagnosis, SDMT, LNS, animal naming were similar between the diagnostic groups, and all cognitive scores were similar between PD-NC and HC. PD-MCI scored lower than HC on MoCA, phonemic fluency, HVLT-R learning and delayed recall. JLO was similar between PD-MCI and HC. PD-MCI scored lower than PD-NC on MoCA, HVLT-R learning and delayed recall, JLO, but showed similar scores as PD-NC on phonemic fluency. There were no significant diagnostic group by sex interactions.

Longitudinal comparisons: The change in cognition over time is demonstrated in Figure 1 (Supplementary Tables 2–3 for results). MoCA, HVLT-R learning and delayed recall, animal naming did not change over time. Phonemic fluency increased, SDMT and LNS decreased, and JLO showed a trend toward decreasing. There were no significant three- or two-way interactions of diagnostic group, sex, or time. Women scored higher on MoCA, HVLT-R learning and delayed recall and lower on JLO. Phonemic fluency, SDMT, LNS, animal naming were similar between men and women. Regarding diagnosis, LNS and animal naming were similar across diagnostic groups. PD-NC scored lower than HC on SDMT, but similarly to HC across all other measures. PD-MCI scored lower than HC on

MoCA, phonemic fluency, HVLT-R learning and delayed recall, JLO, SDMT, and lower than PD-NC on MoCA, phonemic fluency, HVLT-R learning and delayed recall, JLO.

Longitudinal covariate effects: There were several significant covariate effects on cognition (Supplementary Table 3). Years of education had a positive effect on phonemic fluency, HVLT-R learning and delayed recall, JLO, but a negative effect on animal naming. Longitudinal GDS had a negative effect on SDMT. Longitudinal STAI-State had a negative effect on LNS and animal naming. Longitudinal STAI-Trait did not have a significant effect on any cognitive measures. Longitudinal ESS had a negative effect on MoCA, LNS, animal naming. Longitudinal MDS-UPDRS Part III had a negative effect on MoCA, HVLT-R learning and delayed recall, JLO, animal naming.

Discussion

We investigated how cognition changes over time in men and women with de novo PD, with and without MCI. Women performed better on verbal learning and memory, whereas men had better visuospatial functioning. Controls performed better than PD-MCI on general cognitive abilities, verbal learning and memory, visuospatial functioning, and processing speed measures. The PD-NC performed better than PD-MCI on general cognitive abilities, verbal learning and memory, and visuospatial functioning, but had reduced processing speed compared to HC. Across groups, visuospatial function, processing speed, and working memory deteriorated over time. Diagnostic group, sex, and time effects on cognition were independent, and no interactions between these factors were found. Male sex has been associated with more cognitive impairment in PD (Cholerton et al., 2018; but, c.f., Rana, Yousuf, Naz, & Qa'aty, 2012). Our findings revealed that over 4 years, differences between women and men were confined to verbal memory and visuospatial functioning, independent of MCI diagnosis. This cognitive pattern has been previously reported in healthy aging (Munro et al., 2012), and de novo PD with cross-sectional, baseline measures of the same PPMI PD patient sample (R. Liu et al., 2015). In healthy individuals, sex differences in verbal memory have been suggested to be due to different cognitive strategies employed, and to differences in brain language networks between women and men (Andreano & Cahill, 2009). Our findings indicate that sex effects on cognition in de novo PD are similar to those found in healthy aging. We did not find any sex differences in trajectory of scores over time, contrary to reports associating the male sex with a faster cognitive decline in PD (Cholerton et al., 2018). However, this faster rate was reported in patients with over 8 years of PD duration, and our sample consisted of only de novo patients followed for 4 years. As both age and disease progression are important for PD dementia development (Levy et al., 2002; Rana et al., 2012), effects of sex on cognitive decline rate may become more meaningful later in disease. Other methods, including functional and structural neuroimaging, may help show subtler sex differences that may not yet be reflected with cognitive scores. It is also noteworthy that comorbidities and risk factors which may impact cognition in PD (Doiron, Langlois, Dupré, & Simard, 2018) were not evaluated in this study. Future studies are required to clarify whether comorbidities influence the effects of sex in PD. In our sample, clinical course of cognition over 4 years was similar in PD-NC, PD-MCI, and HC. Previous studies have reported faster progression to dementia in PD with baseline MCI (Pigott et al.,

2015), even in de novo PD (Broeders et al., 2013). Given the age effects on dementia development, the discrepancy between these findings and those of Broeders and colleagues (Broeders et al., 2013) may be due to our sample being younger. Although we cannot test this hypothesis, it is also possible that our PD-MCI group is less impaired at baseline, which would explain differences in longitudinal trajectory. The use of alternate HVLT-R, SDMT, and JLO forms for each year, despite mitigating practice effects, may also have contributed to our lack of finding by adding noise to the data. In addition, our measure of decline differs in important ways as we captured the decline in raw scores instead of assessing the percentage of patients with cognitive decline. Finally, the decrease in our sample size over time is significant, and our negative result may be due to a bias toward better-functioning individuals remaining in the study. The increase in phonemic fluency scores over time is somewhat surprising given the deteriorating effects of aging on cognition (Harada, Natelson Love, & Triebel, 2013). This enhanced performance may be due to practice effects, given the repeated use of the same MoCA form, despite use of alternate forms of other measures (i.e., HVLT-R, SDMT, and JLO). This would be consistent with a study showing that phonemic fluency was the only test of 25 measures showing increased scores due to practice effects over a period of 1 year in healthy aging (Bartels, Wegrzyn, Wiedl, Ackermann, & Ehrenreich, 2010). We included longitudinal mood, sleepiness, and motor impairment scores as covariates and found group and/or sex effects in these variables. In healthy elderly, depression was associated with processing speed, working memory, and executive functions deficits, whereas anxiety was associated with better attention and working memory (Dotson et al., 2014). Our results suggest that depression is associated with reduced processing speed, while state anxiety is associated with reduced working memory and linguistic skills. The opposite relationship of anxiety with cognition in healthy adults and our sample (with the majority consisting of PD patients) can be investigated further to establish effects of anxiety on cognition in PD. Worse daytime sleepiness scores were associated with lower scores on MoCA, reduced working memory, and linguistic skills. This is in line with a previous study reporting that excessive sleepiness can predict cognitive decline determined by the Mini Mental State Examination, a brief global cognitive scale (Jausent et al., 2012). As the motor impairment (MDS-UPDRS Part III) progressed over time, MoCA, verbal learning and memory, visuospatial functioning and language deteriorated. This is not surprising as cognitive decline increases over time as the disease progresses and worse motor impairment at baseline may predict future cognitive decline (Broeders et al., 2013; Pigott et al., 2015). However, more direct testing of these variables was beyond the scope of the article and deserves future studies. In addition, the frequency of APOE-e4 carriers was similar across the groups and the sexes, and thus the association was not evaluated further. Future studies could investigate a potential mediating effect of APOE-ε4 on cognitive decline in men and women with PD. In conclusion, sex had similar cognitive effects in de novo PD as healthy individuals, and decline over 4 years did not differ between men and women with de novo PD or between PD-NC and PD-MCI. In early PD, in contrast to findings for AD, sex does not appear to affect cognition differently. We acknowledge that the PPMI includes limited cognitive assessment, and more extensive cognitive batteries may be helpful in further fleshing out sex differences. Use of such batteries would also allow classification of PD-MCI and provide more reliable results as PD-MCI is rather heterogeneous. Future investigations including longitudinal neuroimaging may further

elucidate the course of pathophysiology in women and men with PD, as well as PD-NC and PD-MCI.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (<http://www.ppmi-info.org/data>). For up-to-date information on the study, visit <http://www.ppmi-info.org>. PPMI – a public-private partnership – is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Allergan, Avid Radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Jenali, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, Voyager Therapeutics, and Golub Capital.

References

- Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, ... Emre M (2010). Mild cognitive impairment in Parkinson disease: A multicenter pooled analysis. *Neurology*. 10.1212/WNL.0b013e3181f39d0e
- Andreano JM, & Cahill L (2009). Sex influences on the neurobiology of learning and memory. *Learning and Memory*. 10.1101/lm.918309
- Bartels C, Wegrzyn M, Wiedl A, Ackermann V, & Ehrenreich H (2010). Practice effects in healthy adults: A longitudinal study on frequent repetitive cognitive testing. Retrieved from <http://www.biomedcentral.com/1471-2202/11/118>
- Benedict RHB, Schretlen D, Groninger L, & Brandt J (1998). Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest Reliability. *The Clinical Neuropsychologist*, 12(1), 43–55. 10.1076/clin.12.1.43.1726
- Benton AL, Varney NR, & Hamsher KD (1978). Visuospatial judgment. A clinical test. *Archives of Neurology*, 35(6), 364–367. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/655909> [PubMed: 655909]
- Broeders M, de Bie RMA, Velseboer DC, Speelman JD, Muslimovic D, & Schmand B (2013). Evolution of mild cognitive impairment in Parkinson disease. *Neurology*, 81(4), 346–352. 10.1212/WNL.0b013e31829c5c86 [PubMed: 23794682]
- Brunet HE, Caldwell JZK, & Miller JB (2018). SEX DIFFERENCES IN LEARNING AND MEMORY WITHIN A CLINICAL SAMPLE OF OLDER ADULTS. *Alzheimer's & Dementia*, 14(7), P1307. 10.1016/j.jalz.2018.06.1848
- Burke SL, Hu T, Fava NM, Li T, Rodriguez MJ, Schuldiner KL, ... Laird A (2018). Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by the hippocampal volume or white matter hyperintensities. *Journal of Women and Aging*. 10.1080/08952841.2018.1419476
- Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, ... Edwards KL (2018). Sex differences in progression to mild cognitive impairment and dementia in Parkinson's disease. *Parkinsonism & Related Disorders*, 50, 29–36. 10.1016/J.PARKRELDIS.2018.02.007 [PubMed: 29478836]
- de la Riva P, Smith K, Xie SX, & Weintraub D (2014). Course of psychiatric symptoms and global cognition in early Parkinson disease. *Neurology*, 83(12), 1096–1103. 10.1212/WNL.0000000000000801 [PubMed: 25128183]
- Doiron M, Langlois M, Dupré N, & Simard M (2018). The influence of vascular risk factors on cognitive function in early Parkinson's disease. *International Journal of Geriatric Psychiatry*, 33(2), 288–297. 10.1002/gps.4735 [PubMed: 28509343]

- Dotson VM, Szymkowicz SM, Kirton JW, McLaren ME, Green ML, & Rohani JY (2014). Unique and interactive effect of anxiety and depressive symptoms on cognitive and brain function in young and older adults. *Journal of Depression & Anxiety*, Suppl 1 10.4172/2167-1044.S1-003
- Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, ... Zweig RM (2008). Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. *Movement Disorders*, 23(15), 2129–2170. 10.1002/mds.22340 [PubMed: 19025984]
- Harada CN, Natelson Love MC, & Triebel KL (2013). Normal cognitive aging. *Clinics in Geriatric Medicine*, 29(4), 737–752. 10.1016/j.cger.2013.07.002 [PubMed: 24094294]
- Jausset I, Bouyer J, Ancelin M-L, Berr C, Foubert-Samier A, Ritchie K, ... Dauvilliers Y (2012). Excessive Sleepiness is Predictive of Cognitive Decline in the Elderly. *Sleep*, 35(9), 1201–1207. 10.5665/sleep.2070 [PubMed: 22942498]
- Johns MW (1991). A new method for measuring daytime sleepiness: The Epworth sleepiness scale. *Sleep*. 10.1093/sleep/14.6.540
- Levy G, Schupf N, Tang M-X, Cote LJ, Louis ED, Mejia H, ... Marder K (2002). Combined effect of age and severity on the risk of dementia in Parkinson's disease. *Annals of Neurology*, 51(6), 722–729. 10.1002/ana.10219 [PubMed: 12112078]
- Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, ... Weintraub D (2011). MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. *Movement Disorders : Official Journal of the Movement Disorder Society*, 26(10), 1814–1824. 10.1002/mds.23823 [PubMed: 21661055]
- Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, ... Emre M (2012). Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Movement Disorders*, 27(3), 349–356. 10.1002/mds.24893 [PubMed: 22275317]
- Liu G, Locascio JJ, Corvol J-C, Boot B, Liao Z, Page K, ... Zhang J (2017). Prediction of cognition in Parkinson's disease with a clinical–genetic score: a longitudinal analysis of nine cohorts. *The Lancet Neurology*, 16(8), 620–629. 10.1016/S1474-4422(17)30122-9 [PubMed: 28629879]
- Liu R, Umbach DM, Peddada SD, Xu Z, Tröster AI, Huang X, & Chen H (2015). Potential sex differences in nonmotor symptoms in early drug-naïve Parkinson disease. *Neurology*, 84(21), 2107–2115. 10.1212/WNL.0000000000001609 [PubMed: 25925983]
- Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, ... Taylor P (2011). The Parkinson Progression Marker Initiative (PPMI). *Progress in Neurobiology*. 10.1016/j.pneurobio.2011.09.005
- Meara J, Mitchelmore E, & Hobson P (1999). Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. *Age and Ageing*. 10.1093/ageing/28.1.35
- Munro CA, Winicki JM, Schretlen DJ, Gower EW, Turano KA, Muñoz B, ... West SK (2012). Sex differences in cognition in healthy elderly individuals. *Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition*, 19(6), 759–768. 10.1080/13825585.2012.690366
- Nasreddine ZS, Phillips NA, Bäckström V, Charbonneau S, Whitehead V, Collin I, ... Chertkow H (2005). The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment. *Journal of the American Geriatrics Society*, 53(4), 695–699. 10.1111/j.1532-5415.2005.53221.x [PubMed: 15817019]
- Pigott K, Rick J, Xie SX, Hurtig H, Chen-Plotkin A, Duda JE, ... Weintraub D (2015). Longitudinal study of normal cognition in Parkinson disease. *Neurology*, 85(15), 1276–1282. 10.1212/WNL.0000000000002001 [PubMed: 26362285]
- Rana AQ, Yousuf MS, Naz S, & Qa'aty N (2012). Prevalence and relation of dementia to various factors in Parkinson's disease. *Psychiatry and Clinical Neurosciences*, 66(1), 64–68. 10.1111/j.1440-1819.2011.02291.x [PubMed: 22250611]
- Rosen WG (1980). Verbal fluency in aging and dementia. *Journal of Clinical Neuropsychology*, 2(2), 135–146. 10.1080/01688638008403788
- Samat NA, Abdul Murad NA, Mohamad K, Abdul Razak MR, & Mohamed Ibrahim N (2017). Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients

with Mild Cognitive Impairment. *Frontiers in Neuroscience*, 11, 712 10.3389/fnins.2017.00712 [PubMed: 29326545]

Smith A (1968). The symbol-digit modalities test: A neuropsychologic test of learning and other cerebral disorders. In *Learning disorders*.

Spielberger CD, Gorsuch RL, & Lushene RE (1970). *The State-Trait Anxiety Inventory. MANUAL*. 10.1037/t06496-000

Wechsler D (1997). *WAIS--III: Wechsler Adult Intelligence Scale (3rd ed.) Administration and scoring manual*. The Psychological Corporation, San Antonio, TX.

Fig. 1.
Changes in cognitive scores over time.

Table 1

Means (standard deviations) and statistical comparisons of baseline measures

	Parkinson's disease patients with normal cognition (PD-NC) (n=257)				Parkinson's disease patients with mild cognitive impairment (PD-MCI) (n=167)				Healthy controls (HC) (n=140)		Statistical comparisons		
	Women (n=100)	Men (n=157)	Women (n=45)	Men (n=122)	Women (n=56)	Men (n=84)	Diagnostic group	Sex	Diagnostic group and sex interaction				
Number of participants with years 1/2/3/4 data	82/71/67/59	136/123/116/111	43/40/38/35	105/97/85/76	56/56/54/52	82/81/78/75							
Age	60.03 (9.40)	61.33 (10.45)	62.20 (10.03)	63.15 (8.9)	59.21 (12.33)	61.89 (11.26)	F(2,556)=1.505, $p=0.223$, partial $\eta^2=0.005$	F(1,556)=3.824, $p=0.051$, partial $\eta^2=0.007$	F(2,556)=0.305, $p=0.737$, partial $\eta^2=0.001$				
Years of education	15.67 (2.92)	16.05 (2.90)	14.40 (3.32)	15.20 (2.91)	15.77 (2.77)	16.62 (2.98)	F(2,556)=8.655, $p<0.001$ *, partial $\eta^2=0.030$ -PD-NC vs HC: $p=0.584$ -PD-MCI vs HC: $p<0.001$ *, $p=0.003$ *	F(1,556)=6.614, $p=0.010$ *, partial $\eta^2=0.012$	F(2,556)=0.429, $p=0.651$, partial $\eta^2=0.002$				
Apolipoprotein E- $\epsilon 4$ carriers, %	19.8	29.7	25.6	27.9	31.2	24.4	$\chi^2(2)=0.091$, $p=0.955$, $\phi=0.013$	$\chi^2(1)=0.747$, $p=0.388$, $\phi=0.038$					
Disease duration, months	7.11 (7.72)	5.89 (6.03)	6.24 (6.39)	6.96 (5.94)	n/a	n/a	F(1,403)=0.018, $p=0.894$, partial $\eta^2=0.000$	F(1,403)=0.121, $p=0.728$, partial $\eta^2=0.000$	F(1,403)=1.822, $p=0.178$, partial $\eta^2=0.005$				
15-item Geriatric Depression Scale (GDS)	5.22 (1.37)	5.18 (1.43)	5.36 (1.24)	5.33 (1.55)	5.30 (1.44)	5.11 (1.57)	F(2,556)=0.474, $p=0.623$, partial $\eta^2=0.002$	F(1,556)=0.455, $p=0.500$, partial $\eta^2=0.001$	F(2,556)=0.141, $p=0.869$, partial $\eta^2=0.001$				
State and Trait Anxiety Inventory-State	33.32 (11.37)	31.75 (10.07)	35.23 (10.18)	33.52 (9.40)	28.54 (8.96)	26.83 (7.06)	F(2,556)=17.306, $p<0.001$ *, partial $\eta^2=0.059$ -PD-NC vs HC: $p<0.001$ *, $p<0.001$ *, $p<0.001$ *, $p<0.001$ *, $p=0.224$	F(1,556)=3.421, $p=0.065$, partial $\eta^2=0.006$	F(2,556)=0.003, $p=0.997$, partial $\eta^2=0.000$				
State and Trait Anxiety Inventory-Trait	33.27 (10.23)	31.29 (8.90)	35.91 (10.88)	31.89 (8.65)	30.57 (8.94)	27.87 (5.78)	F(2,556)=9.554, $p<0.001$ *, partial $\eta^2=0.033$ -PD-NC vs HC: $p=0.004$ *	F(1,556)=12.423, $p<0.001$ *, partial $\eta^2=0.022$	F(2,556)=0.556, $p=0.574$, partial $\eta^2=0.002$				

	Parkinson's disease patients with normal cognition (PD-NC) (n=257)				Parkinson's disease patients with mild cognitive impairment (PD-MCI) (n=167)				Healthy controls (HC) (n=140)		Statistical comparisons	
	Women (n=100)	Men (n=157)	Women (n=45)	Men (n=122)	Women (n=56)	Men (n=84)	Diagnostic group	Sex	Diagnostic group and sex interaction			
Epworth Sleepiness Scale	5.76 (3.65)	5.89 (3.56)	4.98 (3.45)	5.94 (3.17)	5.38 (3.17)	5.78 (3.48)	- PD-MCI vs HC: $p<0.001^*$ - PD-MCI vs PD-NC: $p=0.258$	F(1,556)=2.484, $p=0.116$, partial $\eta^2=0.004$	F(2,556)=0.622, $p=0.537$, partial $\eta^2=0.002$			
Movement Disorders Society-Unified Parkinson's Disease Rating Scale Part III	19.24 (8.48)	19.58 (8.59)	23.58 (8.85)	22.73 (10.10)	n/a	n/a	F(1,420)=13.854, $p<0.001^*$, partial $\eta^2=0.032$	F(1,420)=0.192, $p=0.662$, partial $\eta^2=0.000$	F(1,420)=0.049, $p=0.825$, partial $\eta^2=0.000$			
Hoehn and Yahr Stage	1.55 (0.50)	1.53 (0.51)	1.58 (0.54)	1.63 (0.48)	n/a	n/a	F(1,420)=1.420, $p=0.234$, partial $\eta^2=0.003$	F(1,420)=0.086, $p=0.770$, partial $\eta^2=0.000$	F(1,420)=0.467, $p=0.495$, partial $\eta^2=0.001$			
Montreal Cognitive Assessment	28.38 (1.30)	28.06 (1.35)	25.61 (2.58)	25.44 (2.55)	28.43 (1.06)	28.21 (1.12)	F(2,548)=95.094, $p<0.001^*$, partial $\eta^2=0.258$ - PD-NC vs HC: $p=1.000$ - PD-MCI vs HC: $p<0.001^*$ - PD-MCI vs PD-NC: $p<0.001^*$	F(1,548)=1.981, $p=0.160$, partial $\eta^2=0.004$	F(2,548)=0.059, $p=0.943$, partial $\eta^2=0.000$			
Phonemic fluency	13.76 (4.06)	13.32 (5.05)	12.07 (4.46)	12.43 (4.55)	14.48 (3.63)	14.65 (4.87)	F(2,548)=5.126, $p=0.006^*$, partial $\eta^2=0.018$ - PD-NC vs HC: $p=0.084$ - PD-MCI vs HC: $p=0.005^*$ - PD-MCI vs PD-NC: $p=0.114$	F(1,548)=0.282, $p=0.596$, partial $\eta^2=0.001$	F(2,548)=0.250, $p=0.779$, partial $\eta^2=0.001$			
Hopkins Verbal Learning Test-Revised-Learning	27.74 (3.55)	25.69 (4.18)	22.64 (4.98)	20.83 (4.37)	28.14 (3.99)	26.41 (3.92)	F(2,548)=51.064, $p<0.001^*$, partial $\eta^2=0.157$ - PD-NC vs HC: $p=0.975$ - PD-MCI vs HC: $p<0.001^*$ - PD-MCI vs PD-NC: $p<0.001^*$	F(1,548)=26.627, $p<0.001^*$, partial $\eta^2=0.046$	F(2,548)=0.022, $p=0.978$, partial $\eta^2=0.000$			

Variables are reported as mean (standard deviation) or percentage. Statistical significance is marked with *.

PD-NC: Parkinson's disease patients with normal cognition, PD-MCI: Parkinson's disease patients with mild cognitive impairment, HC: healthy controls, n/a: not applicable.